Details for New Drug Application (NDA): 091050
✉ Email this page to a colleague
NDA 091050 describes ABACAVIR SULFATE, which is a drug marketed by Aurobindo Pharma Ltd, Hetero Labs Ltd Iii, Apotex Inc, Cipla, Mylan Pharms Inc, Strides Pharma, Norvium Bioscience, Aurobindo Pharma, Chartwell Rx, Laurus, Teva Pharms Usa, Zydus Pharms, and Lupin Ltd, and is included in seventeen NDAs. It is available from twelve suppliers. Additional details are available on the ABACAVIR SULFATE profile page.
The generic ingredient in ABACAVIR SULFATE is abacavir sulfate; lamivudine; zidovudine. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the abacavir sulfate; lamivudine; zidovudine profile page.
The generic ingredient in ABACAVIR SULFATE is abacavir sulfate; lamivudine; zidovudine. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the abacavir sulfate; lamivudine; zidovudine profile page.
Summary for 091050
| Tradename: | ABACAVIR SULFATE |
| Applicant: | Strides Pharma |
| Ingredient: | abacavir sulfate |
| Patents: | 0 |
Pharmacology for NDA: 091050
| Mechanism of Action | Cytochrome P450 1A1 Inhibitors Nucleoside Reverse Transcriptase Inhibitors |
Suppliers and Packaging for NDA: 091050
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ABACAVIR SULFATE | abacavir sulfate | TABLET;ORAL | 091050 | ANDA | Strides Pharma Science Limited | 64380-717 | 64380-717-01 | 60 TABLET in 1 BLISTER PACK (64380-717-01) |
| ABACAVIR SULFATE | abacavir sulfate | TABLET;ORAL | 091050 | ANDA | Strides Pharma Science Limited | 64380-717 | 64380-717-03 | 60 TABLET in 1 BOTTLE (64380-717-03) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 300MG BASE | ||||
| Approval Date: | Oct 28, 2016 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
